Cellular and Humoral Immunogenicity of ADMVA, a Clade C/B MVA-Based HIV-1 Candidate Vaccine, in Healthy Volunteers. In AIDS Vaccine 2007 Conference. presented at the 20/08/2007, Seattle, WA. Retrieved from http://www.vaccineenterprise.org/conference_archive/2007/index.html. (2007).
Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine, 21-22, 2933-2947. presented at the 2003.. (2003).
Immunization with envelope MN rap 120 vaccine in human immunodeficiency virus infected pregnant women. J Infec Dis, 180, 1080-8. presented at the 1999.. (1999).
Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines. J Infec Dis, 177, 310-319. presented at the 02/1998. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9466516. (1998).
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. J Infec Dis, 177, 1230-46. presented at the 1998.. (1998).